AbbVie合资企业

As tomorrow’s innovations are developed by today’s entrepreneurs, we invest in transformational scientific opportunities aligned with our core R&D interests to gain access to next-generation science and build relationships with proven and emerging scientific leaders.

\r\n"}}" id="text-6a7d95a04b" class="cmp-text">

明天的创新是由今天的企业家,我们投资转型科学机遇与我们的研发核心利益获得新一代科学构建关系证明和新兴科学领袖。

我们AbbVie的企业战略风险资本的手臂

Investing since 2009, we focus exclusively on novel, transformational therapeutics at discovery and pre-clinical stages. Aligning with AbbVie’s strategic focus, our investments address critical needs in oncology, immunology, neuroscience, eye care, and aesthetics. We offer our partners access to AbbVie’s vast internal network of experts in all phases of drug development, from drug discovery through successful commercialization.
\r\n
\r\nOur current portfolio is comprised of over 20 companies based in the US and Europe. Targeting six to eight new investments annually, predominantly at the Seed or Series A stage, we have the capability and flexibility to create new companies, and lead or co-lead a syndicate. Our team of dedicated investing professionals is based in three locations: Boston/Cambridge, Chicago and San Francisco areas.

\r\n"}}" id="text-4ed6481961" class="cmp-text">

投资自2009年以来,我们专注于小说,转换疗法在发现和临床前阶段。AbbVie看齐的战略重点,我们的投资解决关键需求在肿瘤学、免疫学、神经科学、眼保健和美学。我们为合作伙伴提供访问AbbVie庞大的内部网络的专家在药物开发的所有阶段,从药物发现到成功的商业化。狗万正网地址

我们目前的投资组合由20多个公司的总部位于美国和欧洲。每年针对6至8新投资,主要在种子或系列阶段,我们有能力和灵活性来创建新公司,和铅或联合财团。我们的团队专门的投资专业人士是建立在三个地方:波士顿剑桥/芝加哥和旧金山地区。


我们的团队